Related Sites

Related Sites

medical news ireland medical news ireland medical news ireland

NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.



Don't have an account? Register

ADVERTISEMENT

ADVERTISEMENT

Keeping pain at bay

By Damien O’Brien, MPSI - 20th Apr 2026

pain
iStock.com/designer491

An overview of pain management, covering the mechanisms of pain, pharmacological treatment options, and non-pharmacological treatment options

Pain is one of the most common symptomatic complaints in medicine and a leading reason for GP and emergency department visits.

Pain is classified based on duration: Pain lasting less than three months is considered acute, while pain persisting for more than three months is classified as chronic. Acute pain typically has a sudden onset, often resulting from injury, surgery, or inflammation. It usually resolves as the underlying cause heals. Chronic pain, however, can significantly reduce a person’s quality-of-life, and often requires long-term management strategies.1,2

Effective pain management is essential for treating both acute and chronic pain. It requires a multidisciplinary approach, incorporating pharmacological treatments, non-pharmacological interventions, and patient education.2,3

Mechanism of pain

Pain is a complex physiological and neurological process involving the central and peripheral nervous systems. It is typically classified as nociceptive pain or neuropathic pain, each with distinct underlying mechanisms.

Transduction is the first stage of the nociceptive pain pathway, where nociceptors (pain receptors) in the skin, muscles, joints, or organs detect a harmful stimulus, which may be mechanical, thermal, or chemical damage.

Tissue damage triggers the release of pro-inflammatory mediators such as prostaglandins, histamine, and substance P. Nerve fibres transmit pain signals from the nociceptors to the spinal cord, where the signal is processed. In response, the brainstem releases neurotransmitters such as endorphins, serotonin, and noradrenaline to modulate pain perception. The signals then reach the brain, where they are interpreted as pain.

Somatic pain results from the activation of nociceptors in superficial or deep tissues. Superficial somatic pain arises from nociceptor stimulation in the skin or other superficial tissues, whereas deep somatic pain originates from nociceptors in bones, ligaments, tendons, blood vessels, and muscles. Visceral pain, on the other hand, originates from internal organs. It is often widespread and difficult to localise, as visceral nociceptors are not as precisely mapped as somatic ones.1,2

Neuropathic pain results from damage to the nervous system rather than direct tissue injury. It is commonly associated with conditions such as diabetes mellitus, shingles, multiple sclerosis, or nerve compression. This type of pain is often due to nerve fibre damage, leading to increased neuronal firing, as well as changes in nerve conduction and neurotransmitter properties. Unlike nociceptive pain, neuropathic pain is generally not well controlled with standard analgesics and often requires medications that modulate nerve activity.1,2

WHO analgesic ladder

The World Health Organisation (WHO) analgesic ladder provides a stepwise approach to pain management, primarily used in cancer pain, but now also applicable for both acute and chronic pain caused by a wide array of conditions. There are some drawbacks to the WHO analgesic ladder, but it provides a structured approach to pain management in up to 80 per cent of patients.

Step 1. Mild pain: Non-opioid analgesics, such as paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs), with or without adjuvants.

Step 2. Moderate pain: Weak opioids (codeine, tramadol), with or without non-opioid analgesics and with or without adjuvants.

Step 3. Severe pain: Strong opioids (morphine, oxycodone, fentanyl), with or without non-opioid analgesics and with or without adjuvants.

The main principles of the analgesic ladder are ‘by the clock, by the mouth, by the ladder’. This means that analgesics should be taken at regular intervals, orally whenever possible, and initiated at step 1 and titrated upward as required. Each patient should undergo a clinical examination, with a treatment regimen individualised and adjusted according to patient response. Adherence to medication is important to prevent recurrence of pain. One drawback associated with the analgesic ladder is that it does not include non-pharmacological treatment options. Furthermore, it can lead to a false belief that NSAIDs and opioids are safe treatment options simply because they are on step 1 and step 2 of the ladder, which is not always the case.3

Treatment

The main objectives of pain management are to reduce discomfort, improve physical function, minimise adverse effects, and improve quality-of-life in patients experiencing acute or chronic pain. A combination of pharmacological and non-pharmacological strategies may be the most effective method to achieve optimal pain control while minimising the risks associated with medication overuse.3

Pharmacological treatment

Paracetamol

Paracetamol is one of the most commonly used analgesics for mild to moderate pain. It may also be used as an adjunct therapy in treating moderate to severe pain. Paracetamol may also be used for the temporary reduction of fever, but it is not effective in neuropathic pain. It is commonly used for headaches, musculoskeletal pain, osteoarthritis, and post-operative pain. It works primarily by inhibiting cyclooxygenase (COX) enzymes in the central nervous system (CNS), specifically COX-3, although the exact mechanism of action remains unclear. Unlike NSAIDs, it has minimal anti-inflammatory effects. The maximum recommended dose of paracetamol for adults (aged 12 years and older) is 1g every four to six hours, up to a maximum of 4g per day. In children, a weight-based dosing approach is more appropriate, with 15mg/kg per dose recommended. It is available in oral, intravenous, and rectal formulations. Paracetamol is generally safe when used correctly, with a favourable adverse effect profile. The main concern with paracetamol is hepatotoxicity, particularly in overdose or individuals with pre-existing liver disease.2

NSAIDs

NSAIDs are commonly used to treat inflammatory pain due to their anti-inflammatory and analgesic effects. They are indicated in the treatment of conditions such as osteoarthritis, rheumatoid arthritis, musculoskeletal pain, dysmenorrhoea, post-operative pain, and fever. They exert their mechanism of action by inhibiting COX-1 and COX-2 enzymes, thereby reducing prostaglandin synthesis and reducing inflammation. Common NSAIDs available without a prescription include ibuprofen and aspirin, while diclofenac, naproxen, dexketoprofen, celecoxib, and etoricoxib are available with prescription. NSAIDs may be administered orally, topically, rectally, or intravenously. Topical formulations are effective for localised musculoskeletal pain while reducing systemic adverse effects. The main adverse effects of NSAIDs include gastrointestinal problems (ulcers, gastritis, bleeding), cardiovascular risks (increased blood pressure, myocardial infarction, stroke), and renal toxicity (acute kidney injury, electrolyte imbalances). Proton pump inhibitors may be used to reduce gastrointestinal risks. Due to the risk of adverse effects, the lowest effective dose should be used for the shortest duration possible.2

Opioids

Opioids may be used in the treatment of moderate to severe pain. They work by binding to opioid receptors, inhibiting pain transmission by reducing neurotransmitter release. Opioids may be classified based on their potency and duration of action.

Weak opioids, such as codeine and tramadol, may be used for mild to moderate pain. Potent opioids, such as morphine and oxycodone, may be used for severe pain, including post-surgery, cancer pain, and palliative care pain. Short-acting opioids, in immediate-release preparations, provide rapid pain relief and may be used for breakthrough pain, whereas long-acting opioids, in extended-release preparations, may be used for chronic pain management.

Opioids are available in oral, intravenous, intramuscular, subcutaneous, transdermal, and epidural formulations. Adverse effects of opioids include respiratory depression, constipation, nausea, vomiting, sedation, and dependency. Opioid-induced constipation is very common; therefore, laxatives may be co-administered to prevent it. Tolerance and physical dependence can develop with long-term opioid use, which requires careful monitoring and dose adjustments. Opioids should only be used when the expected benefits for both pain relief and function outweigh the risks of addiction, tolerance, and adverse effects.2

Antidepressants

Certain antidepressants, particularly tricyclic antidepressants (TCAs) and serotonin-noradrenaline reuptake inhibitors (SNRIs), are effective for neuropathic pain. Amitriptyline and nortriptyline are examples of TCAs, while duloxetine and venlafaxine are examples of SNRIs used to treat neuropathic pain. They work by enhancing serotonin and noradrenaline levels, which modulate pain perception in the CNS. Furthermore, they may be used for other conditions, including fibromyalgia and chronic musculoskeletal pain, while amitriptyline is often used prophylactically in treating migraine and headache. They are particularly useful if depression or anxiety is a co-morbidity. These drugs are administered orally and are typically taken at night due to their sedative effects. Common adverse effects include nausea, vomiting, drowsiness, dry mouth, dizziness, weight gain, decreased libido, and orthostatic hypotension. TCAs have cardiac risks and should be avoided in patients with pre-existing heart conditions. Patients should be monitored for signs of serotonin syndrome, particularly when other serotonergic drugs are co-administered.2

Anticonvulsants

Anticonvulsant medications, such as gabapentin and pregabalin, are widely used for neuropathic pain conditions, including diabetic neuropathy, and postherpetic neuralgia. They work by reducing the calcium-dependent release of excitatory neurotransmitters, which decreases neuronal excitability and abnormal pain signalling. They are administered orally. Common adverse effects include dizziness, blurred vision, nausea, headache, confusion, and depression. Gradual dose titration helps minimise adverse effects such as dizziness and sedation.2

Non-pharmacological management

There are several non-pharmacological treatment options that can be effective in relieving pain. These include physiotherapy, heat and cold therapy, acupuncture, and exercise programmes delivered by an appropriately trained professional. Cognitive behavioural therapy may also have a role in treating patients with chronic pain, particularly as an adjunct to other therapies.

Non-pharmacological options often have a favourable adverse effect profile when practised correctly. These treatment options can be used alone or combined with pharmacological treatment to form a multi-modal approach. Non-pharmacological strategies may also reduce anxiety associated with pain and lower the dosage of analgesic drugs needed, thereby reducing adverse effects and minimising risk.4

References

Chen J, Kandle PF, Murray IV, Fitzgerald LA, Sehdev JS. Physiology, pain. 2023 Jul 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing

Queremel Milani DA, Davis DD. Pain Management Medications. 2023 Jul 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing

Anekar AA, Hendrix JM, Cascella M. WHO analgesic ladder. 2023 Apr 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing

Dydyk AM, Conermann T. Chronic pain. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024

Leave a Reply

ADVERTISEMENT

Latest

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

Latest Issue
Medical Independent 21st April 2026

You need to be logged in to access this content. Please login or sign up using the links below.

ADVERTISEMENT

Trending Articles

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT